Chardan Capital Reiterates “Buy” Rating for Arrowhead Pharmaceuticals (ARWR)
Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “buy” rating restated by Chardan Capital in a report issued on Monday. They presently have a $24.50 target price on the biotechnology company’s stock. Chardan Capital’s target price points to a potential upside of 41.21% from the company’s previous close.
ARWR has been the topic of a number of other reports. Cantor Fitzgerald set a $24.00 price target on shares of Arrowhead Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, December 11th. William Blair restated an “outperform” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 17th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $21.36.
ARWR opened at $17.35 on Monday. Arrowhead Pharmaceuticals has a 1-year low of $4.77 and a 1-year high of $22.39. The company has a market capitalization of $1.45 billion, a PE ratio of -26.69 and a beta of 2.23.
In related news, VP Zhen Li sold 40,500 shares of the firm’s stock in a transaction that occurred on Monday, January 14th. The shares were sold at an average price of $14.34, for a total value of $580,770.00. Following the completion of the transaction, the vice president now owns 201,700 shares in the company, valued at approximately $2,892,378. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Bruce D. Given sold 242,834 shares of the firm’s stock in a transaction that occurred on Tuesday, February 12th. The shares were sold at an average price of $16.04, for a total transaction of $3,895,057.36. Following the completion of the transaction, the chief operating officer now owns 859,523 shares of the company’s stock, valued at approximately $13,786,748.92. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 972,375 shares of company stock worth $14,143,250. 4.80% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. State Board of Administration of Florida Retirement System raised its holdings in Arrowhead Pharmaceuticals by 10.1% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 38,552 shares of the biotechnology company’s stock valued at $479,000 after buying an additional 3,542 shares during the last quarter. Advisor Group Inc. raised its holdings in Arrowhead Pharmaceuticals by 73.4% in the 4th quarter. Advisor Group Inc. now owns 8,670 shares of the biotechnology company’s stock valued at $109,000 after buying an additional 3,670 shares during the last quarter. Teachers Advisors LLC raised its holdings in Arrowhead Pharmaceuticals by 2.5% in the 3rd quarter. Teachers Advisors LLC now owns 170,714 shares of the biotechnology company’s stock valued at $3,273,000 after buying an additional 4,191 shares during the last quarter. Lindbrook Capital LLC bought a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at approximately $52,000. Finally, Blair William & Co. IL raised its holdings in Arrowhead Pharmaceuticals by 7.0% in the 3rd quarter. Blair William & Co. IL now owns 67,580 shares of the biotechnology company’s stock valued at $1,296,000 after buying an additional 4,410 shares during the last quarter. Institutional investors and hedge funds own 59.52% of the company’s stock.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company offers ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver disease related to alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.